Market Trends of Lice Treatment Industry
This section covers the major market trends shaping the Lice Treatment Market according to our research experts:
Permethrin Segment is Expected to Hold a Major Share in the Market
The Permethrin segment is expected to hold a major share in the market. Permethrin treats scabies in adults and children two months of age and older. Over-the-counter permethrin is used to treat lice (small insects that attach themselves to the skin on the head) in adults and children two months of age and older. Permethrin is in a class of medications called scabicides and pediculicides. It works by killing lice and mites.
According to the study published by the International Journal of Preventive Medicine in February 2021, the infested people were treated with 1% permethrin shampoo, twice at a 1-week interval and other recommended therapeutic categories. 1% permethrin shampoo had high treatment success. It was estimated to be 82.00%. Such data displays the significant use of permethrin in lice treatment. Furthermore, according to NCBI in May 2022, permethrin is a common first-line treatment option for head lice infestations, which is available over the counter in many countries and a systematic review of trials that evaluated medications for the treatment of head lice suggested that permethrin was very much effective.
Therefore, the demand for permethrin is expected to increase, which will significantly drive the overall target market during the study period.
North America Dominates the Market and is Expected to do Same in the Forecast Period
North America is expected to dominate the overall lice treatment market throughout the forecast period. The largest share is mainly due to the presence of a larger infestation pool and an increasing children population.
For instance, the United States Census Bureau, in its 2020 census, showed that the number of children under the age of 18 years was 73.1 million in 2020. Furthermore, according to CDC in September 2020, infestation with head lice is very common among preschool children attending childcare, elementary schoolchildren, and household members of infested children in the United States, and approximately 6 million to 12 million infestations occur each year in the United States among children 3 to 11 years of age. The larger infestation pool and increasing children population are attributing factors to the growth of the market in the United States.
In addition, increasing product approvals is also contributing to market growth. For instance, in July 2020, the United States FDA approved the use of Xeglyze, a drug used to treat head lice in patients six months of age and older. The FDA approved the drug after a clinical trial studying the efficacy of the drug in the prevention of head lice infestation. The study showed that About 80% of patients treated with Xeglyze were free of live head lice.
Thus, due to the above-mentioned developments, the market is expected to witness significant growth over the forecast period.
